Kintai Therapeutics Advances Anti-Obesity Agent KTX-0200 into IND-Enabling Studies Following Positive Preclinical Data Demonstrating Sustained Weight Loss and Improved Health Markers

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs